Agenus

Precision Medicine And Global Aging Will Revolutionize Cancer Care

AnalystHighTarget

Not Invested

Consensus Narrative from 3 Analysts

Published

13 Aug 25

Updated

16 Aug 25

AnalystHighTarget's Fair Value

US$23.00

79.9% undervalued

16 Aug

US$4.63

-12.3%

-3.5%

Author's Valuation

US$23.0

79.9% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$23.0

79.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

8.05%

Biotech revenue growth rate

13.11%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.63%

Calculation

US$42.69m

Earnings '28

47.04x

PE Ratio '28

US$2.01b

Market Cap '28

US$2.01b

Market Cap '28

70.01m

No. shares '28

US$28.68

Share Price '28

US$28.68 Share Price '28

Discounted to 2025 @ 7.64% p.a.

US$23.00

Fair Value '25